Search results
Results from the WOW.Com Content Network
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. [1] It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid , or have HIV/AIDS .
Tetanus immunoglobulin (TIG), [1] also called tetanus antibodies or tetanus antitoxin. [46] It can be given as intravenous therapy or by intramuscular injection. Antibiotic therapy to reduce toxin production. Metronidazole intravenous (IV) is a preferred treatment. [48] Benzodiazepines can be used to control muscle spasms.
Tetanus toxoid can be given in case of a suspected exposure to tetanus. In such cases, it can be given with or without tetanus immunoglobulin (also called tetanus antibodies or tetanus antitoxin [13]). It can be given as intravenous therapy or by intramuscular injection. [citation needed]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [23] [24] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tetanus_immune_globulin&oldid=758991388"
Tdap (also TDP) is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. It was licensed in the United States for use in adults and adolescents on 10 June 2005. [ 26 ] Two Tdap vaccines are available in the US.
In immunology, passive immunity is the transfer of active humoral immunity of ready-made antibodies.Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin (obtained from humans, horses, or other animals) are transferred to non-immune ...
Another breakthrough occurred in 2003. A new technology allowed for heavy and light chain immunoglobulin genes to be amplified from human B cells and cloned into expression vectors. In 2008, this method was refined with a greater ability to sort cells and clone, which led to the discovery of more human monoclonal antibodies.